Vaccine nationalism and the dynamics and control of SARS-CoV-2-Reference-Cited by-同舟云学术

Vaccine nationalism and the dynamics and control of SARS-CoV-2

Published:2021-09-24 Issue:6562 Volume:373 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Wagner Caroline E.¹^ORCID,Saad-Roy Chadi M.²^ORCID,Morris Sinead E.³^ORCID,Baker Rachel E.⁴⁵^ORCID,Mina Michael J.⁶⁷^ORCID,Farrar Jeremy⁸^ORCID,Holmes Edward C.⁹¹⁰¹¹^ORCID,Pybus Oliver G.¹²^ORCID,Graham Andrea L.⁴^ORCID,Emanuel Ezekiel J.¹³^ORCID,Levin Simon A.⁴^ORCID,Metcalf C. Jessica E.⁴¹⁴^ORCID,Grenfell Bryan T.⁴¹⁴^ORCID

Affiliation:

1. Department of Bioengineering, McGill University, Montreal, QC H3A 0C3, Canada.

2. Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08540, USA.

3. Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA.

4. Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ 08540, USA.

5. Princeton High Meadows Environmental Institute, Princeton University, Princeton, NJ 08540, USA.

6. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

7. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

8. The Wellcome Trust, London, UK.

9. Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, Australia.

10. School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW, Australia.

11. School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.

12. Department of Zoology, University of Oxford, Oxford, UK.

13. Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

14. Princeton School of Public and International Affairs, Princeton University, Princeton, NJ 08540, USA.

Abstract

Stockpiling and control A triumph that has emerged from the catastrophe of the severe acute respiratory syndrome coronavirus 2 pandemic has been the rapid development of several potent vaccines. However, 18 months into the pandemic and more than 6 months after vaccine approval, wealthy countries remain the major beneficiaries. Wagner et al . model the consequences of vaccine stockpiling in affluent countries on disease rates in lower- and middle-income countries and the consequences for the eruption of new variants that could jeopardize the early success of vaccines. For countries that can readily access vaccines, it would be better to share vaccines equitably to lower disease burdens in countries with less access, reduce the cost of having to be constantly vigilant for case imports, and minimize virus evolution. —CA

Funder

National Science Foundation

Centers for Disease Control and Prevention

James S. McDonnell Foundation

Google

Open Philanthropy Project

Natural Sciences and Engineering Research Council of Canada

C3.ai Digital Transformation Institute and Microsoft Corporation

Co-operative Institute for Modelling the Earth System

Flu Lab

Publisher

American Association for the Advancement of Science (AAAS)